DarioHealth Unveils Research Showing Sustained Outcomes Post-GLP-1 For Platform Users And 89% Accuracy In Innovative AI Blood Glucose Prediction At ADA 2025

Dario's new research shows sustained outcomes post-GLP-1 for platform users and 89% accuracy in innovative AI blood glucose prediction; the Company is actively working to leverage these findings in commercial discussions

NEW YORK, June 24, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced four new studies presented this past weekend at the 85th Annual American Diabetes Association ("ADA") Scientific Sessions in Chicago. The research, which represents Dario's 25th published study at the ADA's Scientific Sessions over the last decade, includes groundbreaking findings in sustaining GLP-1 weight loss and artificial intelligence ("AI")-powered personalization that highlight the Company's platform's critical contribution in the digital health market.

Key highlights from the research include a dramatic eA1c reduction from 9.0% to 6.7% in GLP-1 users, with users seeing sustained results for six (6) months after medication discontinuation, and AI predictive accuracy of 89% for future glucose levels, demonstrating Dario's unique position to deliver value in the GLP-1 market where payers and employers seek solutions that maximize their investment in these costly medications.

The Company is currently leveraging these findings in ongoing implementations and commercial discussions with payers and self-insured employers seeking integrated solutions for chronic condition management, particularly around GLP-1 optimization programs.
 

Landmark GLP-1 Study Demonstrates Sustainable Results Beyond Medication

The first study examined 715 GLP-1 users and revealed significant clinical improvements for those engaging with Dario's platform. Most importantly, the research showed that users who discontinued GLP-1 medication maintained stable outcomes, reflecting no significant weight or glucose rebound, for at least six (6) months, addressing a critical industry challenge where patients typically experience rebound effects after stopping treatment.

 Key study results included:

• Among continued GLP-1 users with elevated glucose levels, average blood glucose dropped from an eA1c of 9.0% to 6.7%.
• Digital lifestyle engagement activities significantly enhanced outcomes with meal and physical activity logging associated with stronger blood glucose improvements.
  • Weight logging and educational content were linked to greater weight reduction.
• Members who discontinued GLP-1s experienced no significant weight or glucose rebound over six (6) months, with outcomes remaining statistically equivalent to those who continued medication.

These findings underscore the importance of integrated digital tools in supporting medication adherence, optimizing outcomes, and sustaining progress even after GLP-1 treatment ends.